These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 28277882)

  • 1. Investigational therapies for squamous cell lung cancer: from animal studies to phase II trials.
    Shum E; Wang F; Kim S; Perez-Soler R; Cheng H
    Expert Opin Investig Drugs; 2017 Apr; 26(4):415-426. PubMed ID: 28277882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging drugs for squamous cell lung cancer.
    Cheng H; Shcherba M; Kandavelou K; Liang Y; Liu H; Perez-Soler R
    Expert Opin Emerg Drugs; 2015 Mar; 20(1):149-60. PubMed ID: 25557559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Best practice in the treatment of advanced squamous cell lung cancer.
    Ang YL; Tan HL; Soo RA
    Ther Adv Respir Dis; 2015 Oct; 9(5):224-35. PubMed ID: 25902866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.
    Lazzari C; Karachaliou N; Gregorc V; Bulotta A; Gonzalez-Cao M; Verlicchi A; Altavilla G; Rosell R; Santarpia M
    Expert Rev Respir Med; 2017 Jun; 11(6):469-479. PubMed ID: 28467720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigational drugs for treating anal cancer and future perspectives.
    Bustamante L; Frakes J; Hoffe S; Kim R
    Expert Opin Investig Drugs; 2016; 25(1):51-62. PubMed ID: 26560877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer.
    Rijavec E; Genova C; Barletta G; Biello F; Rossi G; Tagliamento M; Dal Bello MG; Coco S; Vanni I; Boccardo S; Alama A; Grossi F
    Expert Opin Investig Drugs; 2017 May; 26(5):551-561. PubMed ID: 28388262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigational drugs for the treatment of cervical cancer.
    Barra F; Lorusso D; Leone Roberti Maggiore U; Ditto A; Bogani G; Raspagliesi F; Ferrero S
    Expert Opin Investig Drugs; 2017 Apr; 26(4):389-402. PubMed ID: 28274154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma.
    Guazzelli A; Bakker E; Tian K; Demonacos C; Krstic-Demonacos M; Mutti L
    Expert Opin Investig Drugs; 2017 Aug; 26(8):933-944. PubMed ID: 28679291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innovative Clinical Trials: The LUNG-MAP Study.
    Steuer CE; Papadimitrakopoulou V; Herbst RS; Redman MW; Hirsch FR; Mack PC; Ramalingam SS; Gandara DR
    Clin Pharmacol Ther; 2015 May; 97(5):488-91. PubMed ID: 25676724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for small-cell lung cancer: emerging evidence.
    Reck M; Heigener D; Reinmuth N
    Future Oncol; 2016 Apr; 12(7):931-43. PubMed ID: 26882955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigational therapies in phase II clinical trials for the treatment of soft tissue sarcoma.
    Martin-Liberal J; Pérez E; García Del Muro X
    Expert Opin Investig Drugs; 2019 Jan; 28(1):39-50. PubMed ID: 30513001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigational drugs for nasopharyngeal carcinoma.
    Ma BBY; Hui EP; Chan ATC
    Expert Opin Investig Drugs; 2017 Jun; 26(6):677-685. PubMed ID: 28446055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding immunotherapy for the treatment of non-small cell lung cancer.
    Thomas R
    Br J Nurs; 2016 Sep; 25(16):S12-7. PubMed ID: 27615536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging drugs targeting PD-1 and PD-L1: reality or hope?
    Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
    Expert Opin Emerg Drugs; 2014 Dec; 19(4):557-69. PubMed ID: 25253438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety of second-line treatment options for non-small cell lung cancer.
    Rossi A; Maione P; Santabarbara G; Sacco PC; Casaluce F; Sgambato A; Barzelloni ML; Palazzolo G; Gridelli C
    Expert Opin Drug Saf; 2017 Apr; 16(4):471-479. PubMed ID: 28276858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in squamous non-small cell lung cancer: evidence beyond predictive biomarkers.
    Genova C; Rijavec E; Grossi F
    Expert Rev Anticancer Ther; 2016; 16(1):1-4. PubMed ID: 26567561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Squamous cell lung cancer: from tumor genomics to cancer therapeutics.
    Gandara DR; Hammerman PS; Sos ML; Lara PN; Hirsch FR
    Clin Cancer Res; 2015 May; 21(10):2236-43. PubMed ID: 25979930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel therapies for advanced squamous cell carcinoma of the lung.
    Koutsoukos K; Mountzios G
    Future Oncol; 2016 Mar; 12(5):659-67. PubMed ID: 26880383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line treatments of small-cell lung cancers.
    Baize N; Monnet I; Greillier L; Quere G; Kerjouan M; Janicot H; Vergnenegre A; Auliac JB; Chouaid C
    Expert Rev Anticancer Ther; 2017 Nov; 17(11):1033-1043. PubMed ID: 28849951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging treatment for advanced lung cancer with EGFR mutation.
    Inal C; Yilmaz E; Piperdi B; Perez-Soler R; Cheng H
    Expert Opin Emerg Drugs; 2015; 20(4):597-612. PubMed ID: 26153235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.